Abstract
The present paper aims to summarize the results regarding serum albumin-based nanoparticles (NPs) for drug delivery purposes. In particular, it focuses on the relationship between their preparation techniques and synthesis parameters, as well as their successful clinical application. In spite of the huge amount of consumed material and immaterial sources and promising possibilities, products made from different types of albumin NPs, with the exception of a few, still have not been invented. In the present paper, promising applications of serum albumin nanoparticles (SANPs) for different biomedical purposes, such as carriers, delivery systems and contrast agents, are also discussed. The most frequent utilization of the NPs for certain diseases, i.e., cancer therapy, and future prospects are also detailed in this study.
Highlights
With the present need for improving health properties through the application of modern, smart, next-generation drug delivery systems (DDS), the application of nanoparticles (NPs) to free drugs is advantageous for several reasons [1,2,3]
Abraxane® is a drug formulation based on serum albumin nanoparticles (SANPs) that garnered more than 600 million dollars in sales in 2012 alone [20] and saw 52% sales growth in 2013 [21]
As albumin has its own role in the body as a blood component, it can count as a therapeutic agent on its own or can be used as a drug carrier system [30], diagnostic agent in the diagnosis of diseases such as tuberculosis and acquired immunodeficiency syndrome (AIDS) [31], and can be used as a coating agent [32,33]
Summary
With the present need for improving health properties through the application of modern, smart, next-generation drug delivery systems (DDS), the application of nanoparticles (NPs) to free drugs is advantageous for several reasons [1,2,3]. With the application of drug delivery systems, poorly soluble drugs can be solubilized to accommodate therapeutic cargoes within their particle cores [4] When these drugs are protected by the carrier and their degradation is prevented, their half-life can be appropriately adjusted and the release of their properties can be sustained [5] or tuned according to the proposed application. From the carrier’s point of view, the next-generation half-life extension and targeted drug-delivery technologies in general should be simple in design, biocompatible, biodegradable and nonimmunogenic. As an exogenous or endogenous carrier protein for treating various diseases—primarily cancer [15], rheumatoid arthritis, diabetes and hepatitis—has demonstrated its potential in the form of products and numerous clinical trials [16]. The aim of this review is to summarize the present possibilities and provide ideas about the potential future utilization technologies
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
